Physician profile
Julie Goodell
NPI 1811270978
$2,800.67
in general payments reported to CMS, 2019-2025
32 companies · $338 in 2025
The $338 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $598 · 2020: $468 · 2021: $497 · 2022: $341 · 2023: $243 · 2024: $315 · 2025: $338.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $877 · Education: $19.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $876.90 |
| Education | $19.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $903.28 | 2019-2023 | |
| Hologic Sales and Service, LLC | $327.32 | 2019-2025 | Novasure, Aptima, Thinprep 2000 Processor |
| Therapeuticsmd, INC. | $272.05 | 2020-2022 | |
| Mayne Pharma Commercial LLC | $223.51 | 2022-2025 | |
| Astellas Pharma US INC | $174.43 | 2023-2024 | Veozah |
| Pfizer INC. | $130.88 | 2019-2023 | |
| Daiichi Sankyo INC. | $73.39 | 2019-2021 | |
| Exeltis, USA INC. | $73.35 | 2022-2024 | Slynd |
| Bayer Healthcare Pharmaceuticals INC. | $65.70 | 2019-2025 | |
| Lupin INC. | $54.64 | 2019-2020 | |
| Sage Therapeutics, LLC | $47.16 | 2024-2025 | Zurzuvae |
| Avion Pharmaceuticals | $45.75 | 2021-2022 | |
| Amag Pharmaceuticals, INC. | $39.77 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $36.18 | 2019-2023 | Gardasil 9 |
| Boston Scientific Corporation | $30.08 | 2019-2020 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $29.88 | 2023-2024 | Myfembree |
| Covidien LP | $27.99 | 2019-2020 | |
| Duchesnay USA Incorporated | $22.01 | 2019 | |
| Uroviu Corporation | $20.86 | 2022 | |
| Convatec INC. | $20.49 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.48 | 2022 | |
| Organon LLC | $17.07 | 2024 | |
| Myovant Sciences INC. | $16.96 | 2022 | |
| Allergan, INC. | $16.90 | 2019 | |
| Agile Therapeutics, INC. | $16.40 | 2022 | |
| Coopersurgical, INC. | $16.38 | 2019 | |
| Vertical Pharmaceuticals, LLC | $15.88 | 2019 | |
| Supernus Pharmaceuticals, INC. | $14.70 | 2025 | Qelbree |
| Novo Nordisk INC | $13.80 | 2019 | |
| Minerva Surgical, INC | $13.12 | 2019 | |
| Smith+Nephew, INC. | $12.33 | 2022 | |
| Coloplast Corp | $10.93 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julie Goodell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.